1 / 26

presented by Clinical Professor Peter K Panegyres MD PhD FRACP

Factors Influencing the Clinical Expression of Intermediate CAG Repeat Length Mutations of the Huntington’s Disease Gene. presented by Clinical Professor Peter K Panegyres MD PhD FRACP. www.ndr.org.au. Paulsen et al, Progress Neurobio 2013; 110, 4. Neurodegeneration Risk Spectrum.

Download Presentation

presented by Clinical Professor Peter K Panegyres MD PhD FRACP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Factors Influencing the Clinical Expression of Intermediate CAG Repeat Length Mutations of the Huntington’s Disease Gene presented by Clinical Professor Peter K PanegyresMD PhD FRACP www.ndr.org.au

  2. Paulsen et al, Progress Neurobio2013; 110, 4

  3. Neurodegeneration Risk Spectrum Mendelian genes Genetic risk factors Non-genetic risk factors

  4. The larger the CAG repeat length, the earlier the Huntington’s disease : the role of gene modifiers Arning & Epplen, Future Neurol, 2012, 94

  5. Modifier gene products on the age at onset in HD

  6. CAG Repeat Counts on the Huntington gene

  7. Intermediate CAG Repeat Lengths

  8. Intermediate CAG Repeat Lengths • Controversies exist with interpretation of intermediate CAG repeat lengths • CAG ≥ 40  PREDICT-HD phenotype • 36-39  might develop HD phenotype with reduced severity and risk of offspring developing HD • 27-35  might have normal phenotype but offspring might develop HD Am J Hum Genet 1998

  9. Intermediate CAG Repeat Lengths • Previous studies 2011 • Longitudinal evaluation: 10 patients, 5 years • Syndrome chorea (perioral), subtle cognitive defects, ataxia • N=4 formal diagnosis HD • Long-term follow-up essential as the experience suggested that medical disorders, treatments, environmental and other genetic factors EARLY J NeurolSci 2011

  10. CAG 38

  11. CAG 39

  12. Intermediate CAG Repeat Lengths • CAG 27-35 • Some might have significant behavioural abnormalities without cognitive or motor defects • CAG 27-35 • Some features of HD with negative work-up for phenocopies • CAG 32 • Had neuropathological evidence of HD • CAG 32-35 • Might be at risk of developing HD, especially if family history

  13. Aim To further elucidate the clinical significance of intermediate CAG repeat lengths using the COHORT database Study groups: CAG = 36-39; CAG = 27-35 FACTORS Premanifest HD Manifest HD

  14. Methods • COHORT • Global longitudinal prospective study to gather genetic and biological information + socioeconomic status from subjects with HD and their families • 2006-2011 • N = 2318 • Baseline (year 1)  demography, medical history, physical exam, neurological exam, vital signs, UHDRS, MMSE, medications, HD gene result • Information collected annually • Univariable logistic regression • Multivariable logistic modelling

  15. Results

  16. Results • CAG 36-39 • N = 3 conversions premanifest manifest • CAG 27-35 • N = 0 no conversions • Probability diagnosis HD • CAG = 36-39 = 25 x (95% CI 3-39) than 27-35 • No demographic differences • CAG 36-39 vs 27-35

  17. Results • CAG = 36-39 • N = 17 manifest at baseline • 54.7% mother with HD (p < 0.001)

  18. Results • Total motor score • Maximal chorea score • Maximal dystonia score • Total functional assessment • Independence scale • Total functional capacity Significant difference CAG 36-39 vs 27-35

  19. Interaction of UHDRS measures with time for patients with intermediate CAG repeat lengths over 4 years

  20. Results • CAG = 36-39 • Total motor score • Maximal chorea score • Maximal dystonia score • Total functional assessment • Independence scale • MMSE Significant differences in manifest HD than those who did not

  21. Results * The OR was also adjusted for gender and the history of psychiatric disease

  22. Conclusion Manifest HD CAG 36-39 • Factors increasing risk • Age • Smoking • Factor reducing risk • Higher education Ageing Smoking Premanifest HD Manifest HD Cognitive Reserve +

  23. Conclusion CAG 36-39 CAG Repeat Length CAG ≥40 Age at onset

  24. Modelling neurodegeneration using the Prion hypothesis Prusiner, Science, 2012; 336: 1511

  25. Acknowledgements • Ellie Shu • Data collection and analysis • Tom HY Chen • Statistical analysis and modelling • Jane Paulsen • Intellectual content • Cheryl MacFarlane • Project management • Staff at NDR

  26. Questions & Answers

More Related